Global and United States Primary Biliary Cirrhosis Drug Market Insights, Forecast to 2026

Global and United States Primary Biliary Cirrhosis Drug Market Insights, Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Primary Biliary Cirrhosis Drug Product Introduction
1.2 Market Segments
1.3 Key Primary Biliary Cirrhosis Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type
1.4.2 Budesonide
1.4.3 FFP-104
1.4.4 GSK-2330672
1.4.5 MBX-8025
1.4.6 NGM-282
1.4.7 Others
1.5 Market by Application
1.5.1 Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Primary Biliary Cirrhosis Drug Market Size, Estimates and Forecasts
2.1.1 Global Primary Biliary Cirrhosis Drug Revenue 2015-2026
2.1.2 Global Primary Biliary Cirrhosis Drug Sales 2015-2026
2.2 Global Primary Biliary Cirrhosis Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Primary Biliary Cirrhosis Drug Historical Market Size by Region (2015-2020)
2.3.1 Global Primary Biliary Cirrhosis Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Primary Biliary Cirrhosis Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Primary Biliary Cirrhosis Drug Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Region (2021-2026)
2.4.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Region (2021-2026)
3 Global Primary Biliary Cirrhosis Drug Competitor Landscape by Players
3.1 Global Top Primary Biliary Cirrhosis Drug Sales by Manufacturers
3.1.1 Global Primary Biliary Cirrhosis Drug Sales by Manufacturers (2015-2020)
3.1.2 Global Primary Biliary Cirrhosis Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Global Primary Biliary Cirrhosis Drug Manufacturers by Revenue
3.2.1 Global Primary Biliary Cirrhosis Drug Revenue by Manufacturers (2015-2020)
3.2.2 Global Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Primary Biliary Cirrhosis Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Primary Biliary Cirrhosis Drug Revenue in 2019
3.2.5 Global Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Primary Biliary Cirrhosis Drug Price by Manufacturers
3.4 Global Primary Biliary Cirrhosis Drug Manufacturing Base Distribution, Product Types
3.4.1 Primary Biliary Cirrhosis Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Primary Biliary Cirrhosis Drug Product Type
3.4.3 Date of International Manufacturers Enter into Primary Biliary Cirrhosis Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Primary Biliary Cirrhosis Drug Market Size by Type (2015-2020)
4.1.1 Global Primary Biliary Cirrhosis Drug Sales by Type (2015-2020)
4.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Type (2015-2020)
4.1.3 Primary Biliary Cirrhosis Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Primary Biliary Cirrhosis Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Type (2021-2026)
4.2.3 Primary Biliary Cirrhosis Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Primary Biliary Cirrhosis Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Primary Biliary Cirrhosis Drug Market Size by Application (2015-2020)
5.1.1 Global Primary Biliary Cirrhosis Drug Sales by Application (2015-2020)
5.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Application (2015-2020)
5.1.3 Primary Biliary Cirrhosis Drug Price by Application (2015-2020)
5.2 Primary Biliary Cirrhosis Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Primary Biliary Cirrhosis Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Primary Biliary Cirrhosis Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Primary Biliary Cirrhosis Drug Price Forecast by Application (2021-2026)
6 United States by Players, Type and Application
6.1 United States Primary Biliary Cirrhosis Drug Market Size YoY Growth 2015-2026
6.1.1 United States Primary Biliary Cirrhosis Drug Sales YoY Growth 2015-2026
6.1.2 United States Primary Biliary Cirrhosis Drug Revenue YoY Growth 2015-2026
6.1.3 United States Primary Biliary Cirrhosis Drug Market Share in Global Market 2015-2026
6.2 United States Primary Biliary Cirrhosis Drug Market Size by Players (International and Local Players)
6.2.1 United States Top Primary Biliary Cirrhosis Drug Players by Sales (2015-2020)
6.2.2 United States Top Primary Biliary Cirrhosis Drug Players by Revenue (2015-2020)
6.3 United States Primary Biliary Cirrhosis Drug Historic Market Review by Type (2015-2020)
6.3.1 United States Primary Biliary Cirrhosis Drug Sales Market Share by Type (2015-2020)
6.3.2 United States Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2015-2020)
6.3.3 United States Primary Biliary Cirrhosis Drug Price by Type (2015-2020)
6.4 United States Primary Biliary Cirrhosis Drug Market Estimates and Forecasts by Type (2021-2026)
6.4.1 United States Primary Biliary Cirrhosis Drug Sales Forecast by Type (2021-2026)
6.4.2 United States Primary Biliary Cirrhosis Drug Revenue Forecast by Type (2021-2026)
6.4.3 United States Primary Biliary Cirrhosis Drug Price Forecast by Type (2021-2026)
6.5 United States Primary Biliary Cirrhosis Drug Historic Market Review by Application (2015-2020)
6.5.1 United States Primary Biliary Cirrhosis Drug Sales Market Share by Application (2015-2020)
6.5.2 United States Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2015-2020)
6.5.3 United States Primary Biliary Cirrhosis Drug Price by Application (2015-2020)
6.6 United States Primary Biliary Cirrhosis Drug Market Estimates and Forecasts by Application (2021-2026)
6.6.1 United States Primary Biliary Cirrhosis Drug Sales Forecast by Application (2021-2026)
6.6.2 United States Primary Biliary Cirrhosis Drug Revenue Forecast by Application (2021-2026)
6.6.3 United States Primary Biliary Cirrhosis Drug Price Forecast by Application (2021-2026)
7 North America
7.1 North America Primary Biliary Cirrhosis Drug Market Size YoY Growth 2015-2026
7.2 North America Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
7.2.1 North America Primary Biliary Cirrhosis Drug Sales by Country (2015-2020)
7.2.2 North America Primary Biliary Cirrhosis Drug Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada
8 Europe
8.1 Europe Primary Biliary Cirrhosis Drug Market Size YoY Growth 2015-2026
8.2 Europe Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
8.2.1 Europe Primary Biliary Cirrhosis Drug Sales by Country
8.2.2 Europe Primary Biliary Cirrhosis Drug Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia
9 Asia Pacific
9.1 Asia Pacific Primary Biliary Cirrhosis Drug Market Size YoY Growth 2015-2026
9.2 Asia Pacific Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
9.2.1 Asia Pacific Primary Biliary Cirrhosis Drug Sales by Region (2015-2020)
9.2.2 Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam
10 Latin America
10.1 Latin America Primary Biliary Cirrhosis Drug Market Size YoY Growth 2015-2026
10.2 Latin America Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
10.2.1 Latin America Primary Biliary Cirrhosis Drug Sales by Country
10.2.2 Latin America Primary Biliary Cirrhosis Drug Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Primary Biliary Cirrhosis Drug Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Primary Biliary Cirrhosis Drug Market Facts & Figures by Country
11.2.1 Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country
11.2.2 Middle East and Africa Primary Biliary Cirrhosis Drug Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 AlbireoPharma
12.1.1 AlbireoPharma Corporation Information
12.1.2 AlbireoPharma Description and Business Overview
12.1.3 AlbireoPharma Sales, Revenue and Gross Margin (2015-2020)
12.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Products Offered
12.1.5 AlbireoPharma Recent Development
12.2 CymaBay Therapeutics, Inc.
12.2.1 CymaBay Therapeutics, Inc. Corporation Information
12.2.2 CymaBay Therapeutics, Inc. Description and Business Overview
12.2.3 CymaBay Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Products Offered
12.2.5 CymaBay Therapeutics, Inc. Recent Development
12.3 Dr. Falk Pharma GmbH
12.3.1 Dr. Falk Pharma GmbH Corporation Information
12.3.2 Dr. Falk Pharma GmbH Description and Business Overview
12.3.3 Dr. Falk Pharma GmbH Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Products Offered
12.3.5 Dr. Falk Pharma GmbH Recent Development
12.4 Enanta Pharmaceuticals, Inc.
12.4.1 Enanta Pharmaceuticals, Inc. Corporation Information
12.4.2 Enanta Pharmaceuticals, Inc. Description and Business Overview
12.4.3 Enanta Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
12.4.5 Enanta Pharmaceuticals, Inc. Recent Development
12.5 GlaxoSmithKline Plc
12.5.1 GlaxoSmithKline Plc Corporation Information
12.5.2 GlaxoSmithKline Plc Description and Business Overview
12.5.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
12.5.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Products Offered
12.5.5 GlaxoSmithKline Plc Recent Development
12.6 Intercept Pharmaceuticals, Inc.
12.6.1 Intercept Pharmaceuticals, Inc. Corporation Information
12.6.2 Intercept Pharmaceuticals, Inc. Description and Business Overview
12.6.3 Intercept Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
12.6.5 Intercept Pharmaceuticals, Inc. Recent Development
12.7 Johnson & Johnson
12.7.1 Johnson & Johnson Corporation Information
12.7.2 Johnson & Johnson Description and Business Overview
12.7.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Products Offered
12.7.5 Johnson & Johnson Recent Development
12.8 MediGene AG
12.8.1 MediGene AG Corporation Information
12.8.2 MediGene AG Description and Business Overview
12.8.3 MediGene AG Sales, Revenue and Gross Margin (2015-2020)
12.8.4 MediGene AG Primary Biliary Cirrhosis Drug Products Offered
12.8.5 MediGene AG Recent Development
12.9 NGM Biopharmaceuticals, Inc.
12.9.1 NGM Biopharmaceuticals, Inc. Corporation Information
12.9.2 NGM Biopharmaceuticals, Inc. Description and Business Overview
12.9.3 NGM Biopharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
12.9.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
12.9.5 NGM Biopharmaceuticals, Inc. Recent Development
12.10 Virobay Inc.
12.10.1 Virobay Inc. Corporation Information
12.10.2 Virobay Inc. Description and Business Overview
12.10.3 Virobay Inc. Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Virobay Inc. Primary Biliary Cirrhosis Drug Products Offered
12.10.5 Virobay Inc. Recent Development
12.11 AlbireoPharma
12.11.1 AlbireoPharma Corporation Information
12.11.2 AlbireoPharma Description and Business Overview
12.11.3 AlbireoPharma Sales, Revenue and Gross Margin (2015-2020)
12.11.4 AlbireoPharma Primary Biliary Cirrhosis Drug Products Offered
12.11.5 AlbireoPharma Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Primary Biliary Cirrhosis Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Primary Biliary Cirrhosis Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Primary Biliary Cirrhosis Drug Market Segments
Table 2. Ranking of Global Top Primary Biliary Cirrhosis Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Budesonide
Table 5. Major Manufacturers of FFP-104
Table 6. Major Manufacturers of GSK-2330672
Table 7. Major Manufacturers of MBX-8025
Table 8. Major Manufacturers of NGM-282
Table 9. Major Manufacturers of Others
Table 10. Global Primary Biliary Cirrhosis Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Primary Biliary Cirrhosis Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Primary Biliary Cirrhosis Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Primary Biliary Cirrhosis Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Primary Biliary Cirrhosis Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Primary Biliary Cirrhosis Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 16. Global Primary Biliary Cirrhosis Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 17. Global Primary Biliary Cirrhosis Drug Sales Share by Manufacturers (2015-2020)
Table 18. Global Primary Biliary Cirrhosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Primary Biliary Cirrhosis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Biliary Cirrhosis Drug as of 2019)
Table 20. Primary Biliary Cirrhosis Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Primary Biliary Cirrhosis Drug Price (2015-2020) (USD/Pcs)
Table 23. Primary Biliary Cirrhosis Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Primary Biliary Cirrhosis Drug Product Type
Table 25. Date of International Manufacturers Enter into Primary Biliary Cirrhosis Drug Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Primary Biliary Cirrhosis Drug Sales by Type (2015-2020) (K Pcs)
Table 28. Global Primary Biliary Cirrhosis Drug Sales Share by Type (2015-2020)
Table 29. Global Primary Biliary Cirrhosis Drug Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Primary Biliary Cirrhosis Drug Revenue Share by Type (2015-2020)
Table 31. Primary Biliary Cirrhosis Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 32. Global Primary Biliary Cirrhosis Drug Sales Share by Type (2021-2026)
Table 33. Global Primary Biliary Cirrhosis Drug Sales by Application (2015-2020) (K Pcs)
Table 34. Global Primary Biliary Cirrhosis Drug Sales Share by Application (2015-2020)
Table 35. Global Primary Biliary Cirrhosis Drug Sales Share by Application (2021-2026)
Table 36. Global Primary Biliary Cirrhosis Drug Sales Market Share Forecast by Application (2021-2026)
Table 37. Global Primary Biliary Cirrhosis Drug Revenue by Application (2015-2020) (US$ Million)
Table 38. Global Primary Biliary Cirrhosis Drug Revenue Market Share Forecast by Application (2021-2026)
Table 39. United States Primary Biliary Cirrhosis Drug Sales (K Pcs) of Key Companies (2015-2020)
Table 40. United States Primary Biliary Cirrhosis Drug Sales Share by Company (2015-2020)
Table 41. United States Primary Biliary Cirrhosis Drug Revenue (US$ Million) by Company (2015-2020)
Table 42. United States Primary Biliary Cirrhosis Drug Sales (K Pcs) by Type (2015-2020)
Table 43. United States Primary Biliary Cirrhosis Drug Sales Share by Type (2015-2020)
Table 44. United States Primary Biliary Cirrhosis Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 45. United States Primary Biliary Cirrhosis Drug Price (K Pcs) by Type (2015-2020)
Table 46. United States Primary Biliary Cirrhosis Drug Sales (K Pcs) by Type (2021-2026)
Table 47. United States Primary Biliary Cirrhosis Drug Sales Share by Type (2021-2026)
Table 48. United States Primary Biliary Cirrhosis Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 49. United States Primary Biliary Cirrhosis Drug Revenue Share by Type (2021-2026)
Table 50. United States Primary Biliary Cirrhosis Drug Price (K Pcs) by Type (2021-2026)
Table 51. United States Primary Biliary Cirrhosis Drug Sales (K Pcs) by Application (2015-2020)
Table 52. United States Primary Biliary Cirrhosis Drug Sales Share by Application (2015-2020)
Table 53. United States Primary Biliary Cirrhosis Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 54. United States Primary Biliary Cirrhosis Drug Sales (K Pcs) by Application (2021-2026)
Table 55. United States Primary Biliary Cirrhosis Drug Sales Share by Application (2021-2026)
Table 56. United States Primary Biliary Cirrhosis Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 57. United States Primary Biliary Cirrhosis Drug Revenue Share by Application (2021-2026)
Table 58. North America Primary Biliary Cirrhosis Drug Sales by Country (2015-2020) (K Pcs)
Table 59. North America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2015-2020)
Table 60. North America Primary Biliary Cirrhosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 61. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2015-2020)
Table 62. Europe Primary Biliary Cirrhosis Drug Sales by Country (2015-2020) (K Pcs)
Table 63. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Country (2015-2020)
Table 64. Europe Primary Biliary Cirrhosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 65. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2015-2020)
Table 66. Asia Pacific Primary Biliary Cirrhosis Drug Sales by Region (2015-2020) (K Pcs)
Table 67. Asia Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Region (2015-2020)
Table 68. Asia Pacific Primary Biliary Cirrhosis Drug Revenue by Region (2015-2020) (US$ Million)
Table 69. Asia Pacific Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2015-2020)
Table 70. Latin America Primary Biliary Cirrhosis Drug Sales by Country (2015-2020) (K Pcs)
Table 71. Latin America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2015-2020)
Table 72. Latin Americaa Primary Biliary Cirrhosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 73. Latin America Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2015-2020)
Table 74. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2015-2020) (K Pcs)
Table 75. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share by Country (2015-2020)
Table 76. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue by Country (2015-2020) (US$ Million)
Table 77. Middle East and Africa Primary Biliary Cirrhosis Drug Revenue Market Share by Country (2015-2020)
Table 78. AlbireoPharma Corporation Information
Table 79. AlbireoPharma Description and Business Overview
Table 80. AlbireoPharma Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. AlbireoPharma Primary Biliary Cirrhosis Drug Product
Table 82. AlbireoPharma Recent Development
Table 83. CymaBay Therapeutics, Inc. Corporation Information
Table 84. CymaBay Therapeutics, Inc. Description and Business Overview
Table 85. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. CymaBay Therapeutics, Inc. Product
Table 87. CymaBay Therapeutics, Inc. Recent Development
Table 88. Dr. Falk Pharma GmbH Corporation Information
Table 89. Dr. Falk Pharma GmbH Description and Business Overview
Table 90. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Dr. Falk Pharma GmbH Product
Table 92. Dr. Falk Pharma GmbH Recent Development
Table 93. Enanta Pharmaceuticals, Inc. Corporation Information
Table 94. Enanta Pharmaceuticals, Inc. Description and Business Overview
Table 95. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Enanta Pharmaceuticals, Inc. Product
Table 97. Enanta Pharmaceuticals, Inc. Recent Development
Table 98. GlaxoSmithKline Plc Corporation Information
Table 99. GlaxoSmithKline Plc Description and Business Overview
Table 100. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. GlaxoSmithKline Plc Product
Table 102. GlaxoSmithKline Plc Recent Development
Table 103. Intercept Pharmaceuticals, Inc. Corporation Information
Table 104. Intercept Pharmaceuticals, Inc. Description and Business Overview
Table 105. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Intercept Pharmaceuticals, Inc. Product
Table 107. Intercept Pharmaceuticals, Inc. Recent Development
Table 108. Johnson & Johnson Corporation Information
Table 109. Johnson & Johnson Description and Business Overview
Table 110. Johnson & Johnson Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Johnson & Johnson Product
Table 112. Johnson & Johnson Recent Development
Table 113. MediGene AG Corporation Information
Table 114. MediGene AG Description and Business Overview
Table 115. MediGene AG Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. MediGene AG Product
Table 117. MediGene AG Recent Development
Table 118. NGM Biopharmaceuticals, Inc. Corporation Information
Table 119. NGM Biopharmaceuticals, Inc. Description and Business Overview
Table 120. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. NGM Biopharmaceuticals, Inc. Product
Table 122. NGM Biopharmaceuticals, Inc. Recent Development
Table 123. Virobay Inc. Corporation Information
Table 124. Virobay Inc. Description and Business Overview
Table 125. Virobay Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. Virobay Inc. Product
Table 127. Virobay Inc. Recent Development
Table 128. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 129. Key Challenges
Table 130. Market Risks
Table 131. Main Points Interviewed from Key Primary Biliary Cirrhosis Drug Players
Table 132. Primary Biliary Cirrhosis Drug Customers List
Table 133. Primary Biliary Cirrhosis Drug Distributors List
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Primary Biliary Cirrhosis Drug Product Picture
Figure 2. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Budesonide Product Picture
Figure 4. FFP-104 Product Picture
Figure 5. GSK-2330672 Product Picture
Figure 6. MBX-8025 Product Picture
Figure 7. NGM-282 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Primary Biliary Cirrhosis Drug Report Years Considered
Figure 14. Global Primary Biliary Cirrhosis Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Primary Biliary Cirrhosis Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Primary Biliary Cirrhosis Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Primary Biliary Cirrhosis Drug Sales Market Share by Region in 2019
Figure 19. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Region in 2019
Figure 21. Global Primary Biliary Cirrhosis Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Primary Biliary Cirrhosis Drug Revenue in 2019
Figure 23. Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type in 2019
Figure 26. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type in 2019
Figure 28. Global Primary Biliary Cirrhosis Drug Market Share by Price Range (2015-2020)
Figure 29. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application in 2019
Figure 31. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Application in 2019
Figure 33. United States Primary Biliary Cirrhosis Drug Sales Growth Rate 2015-2026 (K Pcs)
Figure 34. United States Primary Biliary Cirrhosis Drug Revenue Growth Rate 2015-2026 (US$ Million)
Figure 35. United States Primary Biliary Cirrhosis Drug Market Share in Global Market 2015-2026
Figure 36. United States 5 and 10 Largest Primary Biliary Cirrhosis Drug Players Market Share by Revenue in Primary Biliary Cirrhosis Drug in 2019
Figure 37. United States Primary Biliary Cirrhosis Drug Revenue Share by Type (2015-2020)
Figure 38. United States Primary Biliary Cirrhosis Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 39. United States Primary Biliary Cirrhosis Drug Revenue Share by Application (2015-2020)
Figure 40. United States Primary Biliary Cirrhosis Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 41. North America Primary Biliary Cirrhosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. North America Primary Biliary Cirrhosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. North America Primary Biliary Cirrhosis Drug Sales Market Share by Country in 2019
Figure 44. North America Primary Biliary Cirrhosis Drug Revenue Market Share by Country in 2019
Figure 45. U.S. Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. U.S. Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. Canada Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Canada Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Europe Primary Biliary Cirrhosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 50. Europe Primary Biliary Cirrhosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 51. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Country in 2019
Figure 52. Europe Primary Biliary Cirrhosis Drug Revenue Market Share by Country in 2019
Figure 53. Germany Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Germany Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. France Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. France Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. U.K. Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 58. U.K. Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Italy Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 60. Italy Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Russia Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 62. Russia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Asia Pacific Primary Biliary Cirrhosis Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 64. Asia Pacific Primary Biliary Cirrhosis Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 65. Asia Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Region in 2019
Figure 66. Asia Pacific Primary Biliary Cirrhosis Drug Revenue Market Share by Region in 2019
Figure 67. China Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. China Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Japan Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Japan Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. South Korea Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. South Korea Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. India Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. India Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Australia Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Australia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Taiwan Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Taiwan Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Indonesia Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Indonesia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Thailand Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Thailand Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Malaysia Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Malaysia Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Philippines Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 86. Philippines Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Vietnam Primary Biliary Cirrhosis Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 88. Vietnam Primary Biliary Cirrhosis Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Latin America

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Histone Deacetylase (HDAC) Inhibitors Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 87

The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ 615.2 million in 2023 and is anticipated to reach US$ 1223.2 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. North American market for Histone Deacetylase (HDAC) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Histone Deacetylase (HDAC) Inhibitor......

Global Esomeprazole Magnesium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74

The global Esomeprazole Magnesium market was valued at US$ 5287 million in 2023 and is anticipated to reach US$ 9451.5 million by 2030, witnessing a CAGR of 8.3% during The forecast period 2024-2030. North American market for Esomeprazole Magnesium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Esomeprazole Magnesium is estimated to increase from $ million in 2......

Global Combination Therapy Drug Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Combination Therapy Drug market was valued at US$ 105 million in 2023 and is anticipated to reach US$ 166.7 million by 2030, witnessing a CAGR of 4.1% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is......

Global Axitinib Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 68

The global Axitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The......

Global Lyme Disease Vaccine Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 70

The lyme disease vaccine can reduce lyme disease incidence, reduce symptoms and reduce mortality. Lyme disease is a tick-borne infection of spirochete, a natural disease caused by borrelia burgdorferi. The global Lyme Disease Vaccine market was valued at US$ 257 million in 2023 and is anticipated to reach US$ 763 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at......

Global Transdermal Absorption Patch Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Transdermal Absorption Patch market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Transdermal Absorption Patch is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Transdermal Absorption Patch is estimated to increase from $ million i......

Global Ketoprofen Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

Ketoprofen patch, indications for The treatment of symptoms caused by The following diseases: rheumatoid arthritis and rheumatoid arthritis The global Ketoprofen Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Ketoprofen Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast per......

Global Methyl Salicylate Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 82

The global Methyl Salicylate Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to......

Global Diclofenac Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Diclofenac Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs